Structures by: Putra O. D.
Total: 12
2(C20H19ClF3N3O4),0.5(H2O)
2(C20H19ClF3N3O4),0.5(H2O)
CrystEngComm (2020)
a=9.0757(3)Å b=11.0502(4)Å c=11.7199(5)Å
α=103.378(3)° β=105.493(3)° γ=104.407(3)°
C20H19ClF3N3O4
C20H19ClF3N3O4
CrystEngComm (2020)
a=9.1429(4)Å b=11.0950(5)Å c=11.6725(5)Å
α=103.187(4)° β=105.203(4)° γ=104.668(4)°
C20H19ClF3N3O4
C20H19ClF3N3O4
CrystEngComm (2020)
a=9.4219(6)Å b=11.2659(6)Å c=11.5862(6)Å
α=107.504(4)° β=100.890(5)° γ=104.746(5)°
Ciprofloxacin Hydrochloride Anhydrous Form II
C17H19FN3O3,Cl
CrystEngComm (2020)
a=12.4523(2)Å b=6.91819(13)Å c=19.4137(4)Å
α=90° β=101.2940(9)° γ=90°
Ciprfloxacin Hydrochloride Anhydrous Form I
C17H19FN3O3,Cl
CrystEngComm (2020)
a=18.1041(6)Å b=7.30090(17)Å c=26.2525(10)Å
α=90.0° β=90.0° γ=90.0°
Amodiaquine Dihydrochloride Dihydrate
C20H24ClN3O,2(Cl),2(H2O)
CrystEngComm (2019) 21, 13 2053
a=7.69610(14)Å b=10.9153(2)Å c=27.2368(5)Å
α=90° β=96.1341(7)° γ=90°
Epalerstat. DMF solvate
C15H13NO3S2,C3H7NO
CrystEngComm (2017)
a=7.6999(3)Å b=8.7601(3)Å c=15.1662(5)Å
α=102.148(7)° β=95.754(7)° γ=110.011(8)°
2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]
C8H10N4O2,C15H13NO3S2
CrystEngComm (2017)
a=7.7900(4)Å b=8.4073(4)Å c=19.8594(10)Å
α=84.159(3)° β=88.907(2)° γ=62.877(3)°
Epalerstat. 2 DMSO
C15H13NO3S2,2(C2H6OS)
CrystEngComm (2017)
a=8.0773(2)Å b=9.3224(2)Å c=16.0729(3)Å
α=99.322(7)° β=91.404(6)° γ=108.099(8)°
Ciprofloxacin Hydrochloride 1.43 Hydrate
C17H19FN3O3,0.215(H4O2),Cl,H2O
CrystEngComm (2020)
a=7.02521(13)Å b=19.6681(4)Å c=12.9331(2)Å
α=90° β=90.7338(7)° γ=90°
Epalerstat acetone monosolvate
C15H13NO3S2,C3H6O
Acta Crystallographica Section E (2017) 73, 8 1264-1267
a=7.96230(10)Å b=8.1806(2)Å c=15.6919(3)Å
α=97.852(7)° β=99.837(7)° γ=113.206(8)°
Epalrestat tetrahydrofuran monosolvate
C15H13NO3S2,C4H8O
Acta Crystallographica Section E (2017) 73, 7 941-944
a=7.8956(3)Å b=8.9627(3)Å c=15.0311(4)Å
α=102.263(7)° β=93.970(7)° γ=114.219(8)°